Company Intelligence

Nabla Bio

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while…

In this profile

Quick Facts

  • Founded 2020
  • Headquarters Boston, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Growth
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

Why It Matters

We use AI to design antibodies for intractable diseases

Recent Developments

  1. 2020 Company founded

    Nabla Bio was founded in 2020 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe